The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
Therapeutic Pipeline Program, 2016Effect of HDAC Inhibition in Models of Parkinson's Disease
Study Rationale:
Numerous publications have linked the family of epigenetic enzymes known as HDACs (histone deactylases) to the underlying pathology of Parkinson's. This study will test the efficacy of... -
Parkinson’s Disease Therapeutics Pipeline Program, 2025ACT-02 as a Disease-modifying Therapy for Parkinson’s
Study Rationale: Parkinson’s disease (PD) is a complex neurodegenerative disorder marked by the loss of dopaminergic neurons, however the underlying exact reasons are still not fully understood...
-
Rapid Response Innovation Awards, 2007Everyday Action Impairment in People with Parkinson's Disease Dementia/Dementia with Lewy Bodies
Objective/Rationale:
Parkinson’s disease (PD) and Parkinson’s Disease Dementia/Dementia with Lewy Bodies (PDD/DLB) have been associated with cognitive deficits and everyday action impairment (EAI; e.g... -
Cognitive Deficits and Mood Disorders in Parkinson's Disease, 2008A Rodent Model of Pathological Gambling Associated with Medicated Parkinsonian Patients
Objective/Rationale:
The increase in impulsive and risky behaviors, like gambling, hyper-sexuality, and compulsive shopping are emotionally and financially devastating, and impose a significant burden... -
Biomarkers, 2011Identifying Peripheral Inflammatory Markers for Parkinson's Disease with Dementia (PDD)
Objective/Rationale:
Patients with Parkinson’s disease (PD) are at a 5.9 times greater risk of developing dementia than the normal population. The identification of sensitive molecular and cellular... -
Rapid Response Innovation Awards, 2008Effects of noradrenergic or serotoninergic system lesions combined with NS lesions on rodent models of 'non-motor'-like symptoms
Objective/Rationale:
Parkinson’s disease is widely attributed to neuropathy of dopaminergic neurones in the nigrostriatal (NS) pathway. Degeneration of noradrenergic and serotonergic neurones in the...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.